Cells for Sight News Publication
- New research programme into Aniridia to go ahead at Moorfields Eye Hospital
- CFS will give five paper presentations and two posters at ARVO
- Hannah Levis awarded ARVO International Travel Grant
- UCLB patented technology used to develop a potential new treatment for Corneal Surface Disease
- Stefan Schrader successfully defends his PhD thesis
- Cells for Sight to host 5th Limbal Stem Cell Conference at UCL
- Hannah Levis appears in ESCRS Eurotimes
- Prof Julie Daniels invited speaker at the Gordon Conference in California
- Hannah Levis presents at the BCLA Evening Meeting
- New Postdoc joins the group
- Congrats to Marc for running the Paris Marathon!
- Julie Daniels interview on Insight Radio
- Eye disease cash for TAP Biosystems
- TAP, UCL Receive Additional Funding to Take Biomimetic Cornea into Human Safety Study
- New Scientific Data on use of Stem Cells for Ocular Surface Regeneration Presented by Daniels’ Group at Prestigious Ophthalmology Conference, ARVO
- ARVO 2012 report
- International Conference on Stem Cells and Regenerative Medicine
- Julie Daniels Fellow of the Society of Biology
- Welcome to Nuria Genicio!
- London 2012 Olympics is here!
- Farewell Marina!
- Welcome Sara Galindo!
- New research technician joins CFS
- 5th Limbal Stem Cell Meeting
- Recent Publications from CFS
- Alvena visits Prof. Funderburgh's lab in Pittsburgh
- Sarah and Alvena present at London Matrix Group
- Levis et al. manuscript accepted for publication in PLOS ONE
- Amanda Vernon successfully upgrades from MPhil to PhD
- We welcome a new member of CfS- Louise Morgan
- CfS do Movember!
- CfS Christmas Lunch
- New Endothelial RAFT article published in PLOS ONE available online now
- Aniridia Europe Meeting, Italy 2012
- CfS awarded UCL Beacon Bursary to host public engagement event
- Marc Dziasko successfully upgrades from MPhil to PhD
- Hannah and Victoria attend Aniridia Network UK Conference
- Alvena and Isobel visit Istanbul to attend TERMIS
- Marc attends the ISSCR annual conference
- Julie, Louise, Alex and Steve visit Japan
- Hannah and Marc present at the Vision of Excellence Congress in Berlin
- Cells for Sight team attend the 6th Limbal Stem Cell Forum in Liverpool
- Hannah has her paper published in Biomaterials
- Alex has his paper published in Stem Cells Translational Medicine
- Cornea Connect 2014
- Marc Dziasko has his paper published in PLoS ONE
- Hannah and Victoria raise £115 for Aniridia Network UK
- Cells for Sight team prepare for ARVO
- Julie receives PhD studentship funding from Fight for Sight
TAP, UCL Receive Additional Funding to Take Biomimetic Cornea into Human Safety Study
30 April 2012
TAP Biosystems has been awarded additional funding from the U.K.’s Technology Strategy Board to support further development of a biomimetic cornea and progress the product into preclinical development and a first-in-man safety trial in two patients.
The firm will continue its ongoing partnership with a team at the Institute of Ophthalmology at University College London (UCL) to develop a RAFT (real architecture for 3-D tissue) production technology for generating clinical-grade tissues. Developed by TAP in collaboration with tissue engineering academics, RAFT is designed to enable the creation of complex 3-D cell cultures from collagen, consistently and reproducibly, in a simple-to-use format.
Head of the UCL team, Julie Daniels, M.D., has been collaborating
with TAP since 2008. Her work has already demonstrated that RAFT tissues
seeded with epithelial stem cells can generate corneal tissue that
closely mimics the cells’ in vivo environment and supports stem cell
growth, offering potential benefits for ocular surface transplant technology.
“There is a genuine clinical problem with some biomaterials used to
culture and transplant cells," Dr. Daniels remarks. “The RAFT process
creates a natural collagen scaffold that can be engineered to replicate
features of the stem cell niche and is a more realistic environment to
support the stem cell population. The additional funding we have
received from the Technology Strategy Board is a great vote of
confidence in the potential of RAFT to deliver a corneal tissue
equivalent, which we believe will be more effective in treating patients
with blinding corneal surface damage.”
Published 26th April 2012 in Genetic Engineering and Biotechnology News
Page last modified on 30 apr 12 09:38